Merck Serono Appoints Luciano Rossetti Global Head R&D

Merck Serono, the biopharmaceutical division of Merck, has appointed Dr Luciano Rossetti, Executive Vice President and Global Head of Research and Development, with effect from 21 July 2014.

In his most recent position, the Italian Rossetti (57) Senior Vice President of Late Stage Development was at Merck Sharp & Dohme (MSD). In this role he was responsible for the overall clinical development of Phase II to Phase V of all therapeutic disciplines away. Rossetti has the design and implementation of the development strategy for some potentially groundbreaking products such as anti-PD-1 significantly influenced at MSD. He has also restructured the field of clinical genetics to better interlink research and clinical development. Before Rossetti joined MSD in 2006, he worked for 18 years as an internationally recognized academic scientists.

"I am very pleased to welcome Luciano Rossetti at Merck," said Belén Garijo, President and CEO of the Merck Serono division. "With his wealth of experience, his successes in research and development, as well as his strong leadership profile, Luciano will contribute significantly to the development of our promising pipeline."